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Objectives: Many Canadians use prescription medicines that are unnecessary or that can lead
to adverse events. In response, many provinces have introduced programs in which phar-
macists are paid to perform medication reviews with patients. As the evidence on such pro-
grams is equivocal, we investigated the impact of British Columbia's program.
Design: Interrupted time series.
Setting: British Columbia, Canada.
Participants: All residents of British Columbia who received a medication review between
May 1, 2012, and June 30, 2013 (163,776 individuals).
Intervention: Using British Columbia's population-based PharmaNet drug utilization system,
we collected data on community pharmacisteled medication reviews. The PharmaNet data-
base contains a record of all medication reviews conducted in an ambulatory setting.
Main outcome measures: We studied the impact of ﬁrst medication reviews conducted be-
tween May 2012 and June 2013. We used interrupted time series analysis to assess longitu-
dinal changes in patients receiving a standard review (n ¼ 147,770) and a more intensive
pharmacist consultation (n ¼ 16,006). Our outcomes included drug utilization, costs, poten-
tially inappropriate prescriptions, and medication persistence measured through the propor-
tion of commonly used chronic medications that were eventually reﬁlled.
Results: Overall, we observed few changes in the level or trend of any of the outcomes we
studied. Both review types were followed by signiﬁcant increases in both the number of
prescriptions per month and expenditures. The continuation of long-term medications did not
change for 3 of 4 classes, and increased very slightly for the ﬁnal class. We found no evidence
of deprescribing, either for classes that are potentially problematic for long-term use (ben-
zodiazepines and proton pump inhibitors) or for potentially inappropriate prescriptions in
seniors.
Conclusions: Our results suggest that medication reviews did not signiﬁcantly modify prescription
drugusebyrecipients. Future iterationsofsuchprogramsmightbemodiﬁedtobebetter targetedand
to encourage closer collaboration between pharmacists and prescribing health care professionals.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).mmunity pharmacist in
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n®. Published by Elsevier IPrescription drugs are a fundamental part of modern health
care. However, many patients use prescriptions that are un-
necessary or lead to adverse outcomes.1 Canadians take an
average of 16 prescriptions every year, and 1 in 8 adults
experience adverse drug events from drugs prescribed in
ambulatory care settings.2,3 Furthermore, estimates suggest
that 1 of 9 emergency department visits are related to
potentially preventable drug-related adverse events.4 These
medication issues often arise through complex medication
regimens involving multiple prescribers, including both pri-
mary care physicians and specialists.5,6
One increasingly popular effort to improve prescription
drug use is medication reviews by community pharmacists.
A medication review is an individualized, in-personnc. This is an open access article under the CC BY-NC-ND license (http://
Key Points
Background:
 Prescription drug use is often sub-optimal in ambu-
latory settings, resulting in unnecessary drug use,
adverse events, and potentially preventable poor
outcomes. Complexmedicine regimens andmultiple
prescribers are related to the risk of adverse drug-
related events.
 To address some of these medication-related chal-
lenges, many jurisdictions have increased the scope
of practice of community-based pharmacists to
perform medication reviews. Medication review
programs have been implemented internationally,
including in 8 of 10 Canadian provinces.
 The existing evidence on the effectiveness of these
programs is equivocal.
Findings:
 BetweenMay 2012 and June 2013, pharmacists in the
Canadian province of British Columbia conducted
nearly 300,000 medication reviews.
 Using a rigorous longitudinal research design, we
found no evidence that medication reviews reduced
drug costs, improved adherence, or led to the depres-
cribing of potentially inappropriate prescriptions.
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SCIENCE AND PRACTICEappointment in which a pharmacist assesses a patient's cur-
rent medications, discusses their medications with them, and
makes suggestions to optimize their drug therapies. An
explicit goal of most medication review programs is to
improve patient health outcomes.7 A secondary goal is to help
patients to consolidate their prescriptions to decrease unnec-
essary pharmacy visits and encourage patient loyalty to a
single pharmacy.8 In 2007, Ontario became the ﬁrst province in
Canada to implement a government-sponsored program to
compensate community pharmacists for conducting medica-
tion reviews for eligible patients.9 Since then, 7 other Canadian
provinces have implemented similar programs.10
While the use of medication reviews has increased
dramatically, there remains uncertainty regarding their effec-
tiveness.11 One systematic review of interventions targeting
adults with uncontrolled hypertension and diabetes found
that pharmacist-led medication reviews had beneﬁcial effects
on blood pressure and HbA1c glycosylated hemoglobin.12
However, systematic reviews and randomized controlled tri-
als involving interventions targeted to older people found no
effect of these reviews onmortality or hospital admissions.13,14
To date, studies of Canadian medication review programs have
focused on pharmacist, patient, and physician perceptions of
these services.15,16 These studies found that while pharmacists
believed that their job satisfaction and patient knowledge of
medications were positively inﬂuenced by medication review
programs, there was a negative effect on their workload.
Pharmacists also identiﬁed a number of barriers to conducting
medication reviews, such as lack of time to conduct thorough
reviews and inadequate dedicated space to conduct re-
views.15,16 However, no Canadian studies have quantitatively514measured outcomes such as changes in medicine use and
persistence.
Objectives
Despite the equivocal international evidence, the lack of
Canadian data, and uncertainty of the impact of medication
reviews by community pharmacists, provincial governments
in Canada collectively paid more than CAD $96 million for
medication review services in community settings in 2014.17,18
Therefore, we studied the impact of the British Columbia
medication review program on drug utilization, costs, and
medication persistence.
Methods
Study context
British Columbia (BC) began compensating community
pharmacists for performing medication reviews in April
2011. Patients needed to meet at least 1 of several criteria for
a clinical need for the service based on the assessment of the
pharmacist. From May 2012, eligible patients were required
to have been dispensed at least 5 different medications or
insulins over the past 6 months. Eligible medications
included prescription medications, over-the-counter medi-
cations, compounded drug products, and injection drugs.
The BC provincial government funded 3 types ofmedication
review services: standard (MR-S), pharmacist consultation
(MR-PC), and follow-up (MR-F). During an MR-S, the patient
and pharmacist review the patient's medications to improve
their use and understanding of their treatments. The pharma-
cist prepares a “bestpossiblemedicationhistory” for thepatient
with a list of the medications that the patient can take home
with them,anda copywithprofessionalnotes that is keptonﬁle
and can be sent to another health care provider upon request. If
a pharmacist identiﬁes at least 1 drug therapy problem during
the reviewand takes action to resolve it, theymaymake a claim
for an MR-PC instead. An MR-F, available to patients who
received an MR-S or MR-PC in the preceding 12 months, is
intended to update the patient's best possible medication his-
tory following medication changes. Patients were eligible to
receive 1 MR-S or MR-PC review in each 6-month period, and
may have received up to 4 MR-F reviews in the 12 months
following an MR-S or MR-PC. Pharmacists were compensated
$60 for an MR-S, $70 for an MR-PC, and $15 for an MR-F.
Data sources and study population
We used the BC PharmaNet system, a population-based
administrative database of all prescription drug dispensa-
tions in community and hospital outpatient settings in BC.19
Using PharmaNet, we captured data on individual pre-
scriptions, including drug type, total cost, and the number of
units dispensed between December 2010 and June 2014. It also
included data on billings for medication review services,
including the date and type of medication review that was
performed.
Our analyses focused on 2 population-based open cohorts
of individuals who received their ﬁrst medication review be-
tweenMay 1, 2012, and June 30, 2013. The ﬁrst cohort included
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SCIENCE AND PRACTICEpatients whose ﬁrst review was an MR-S (MR-S cohort, n ¼
147,770), and the second included patients whose ﬁrst medi-
cation review was an MR-PC (MR-PC cohort, n ¼ 16,006). We
analyzed these groups separately to investigate whether out-
comes differed between the different medication review
types. Our cohorts excluded patients who received 1 or more
medication review before May 1, 2012 (n ¼ 44,196), and those
whose ﬁrst recorded medication review was an MR-F (n ¼
2870). To ensure that our cohorts were continuously present in
BC during the entire study period, we also excluded patients
who did not have at least 1 prescription every 6months during
the study period (n ¼ 23,933). For each individual in our ﬁnal
analytic cohorts, we identiﬁed their ﬁrst, or index, medication
review and assessed data for the 12 months following this
index review.
Measures
We studied the impact of pharmacist medication reviews
on a range of outcomes.
Prescription drug use and costs
We calculated the average number of prescriptions
dispensed per patient per month. Similarly, we calculated the
total expenditure, per capita per month, by all payers over the
study period.
Patient medication persistence
To study the impact of medication reviews on patient
medication persistence, we calculated the proportion of pre-
scriptions that were reﬁlleddor continueddfor several major
drug classes. We deﬁned a prescription as reﬁlled if the same
active ingredient was dispensed again within the days' supply
of the original prescription plus 30 days. We studied reﬁlls of
several evidence-based long-term therapiesdstatins, diabetes
medications, and antihypertensive medicationsdand 2
classes generally not recommended for long-term used
benzodiazepines and proton pump inhibitors (PPIs).20-23 We
identiﬁed all drugs within these classes using ATC categories.24
Potentially inappropriate prescriptions
To examine whether medication reviews changed poten-
tially problematic prescription drug utilization, we examined
the rate of potentially inappropriate prescriptions (PIPs)
dispensed to patients aged 65 or older, using Beer's criteria.20,21
Pharmacy use patterns
Finally, we studied the impact of medication reviews on
pharmacy visits and loyalty. It was hypothesized by the BC
Pharmacy Association that medication reviews could improve
the relationship between pharmacists and their clients, lead-
ing to an increase in loyalty to a single pharmacy. We calcu-
lated the mean number of unique visits to any pharmacy per
month per patient, considering all prescriptions ﬁlled at the
same pharmacy on the same day as 1 visit. To investigate
loyalty, we calculated the average number of unique phar-
macies visited per patient per month.Statistical analysis
We explored longitudinal changes in the above outcomes
among our 2 cohorts using interrupted time series analysis (ITS),
one of the strongest quasi-experimental research designs.25 ITS
has been used in many pharmaceutical policy evaluations,
including several using the BC PharmaNet datasets.26-31 Using
ITS,we estimated the change in the level and the trend (i.e., slope)
of each outcome following a patient's index medication review.
Asmonthly observationsmay have been correlated over time,we
controlled for autocorrelation using appropriate adjustments for
each model in a segmented regression using a generalized least
squares model.27 We also conducted sensitivity analyses, which
excluded the month of the medication review to account for
the impact of many medication reviews being co-timed with
prescription reﬁlls (resultsnot reported). Please refer toAppendix 1
for a more detailed description of the methods.Results
Use of medication reviews
Between May 1, 2012, and June 30, 2013, pharmacists
conducted 298,319 MR-S and MR-PC medication reviews
(Table 1). MR-S reviews accounted for 89.4% of all reviews,
with 266,786 reviews delivered to 147,770 unique patients.
MR-PC reviews were used less, with only 31,533 reviews
(10.6%) delivered to 16,006 unique patients. More than 57%
of recipients of these reviews were female, and almost 47%
were age 65 years older. The delivery of these reviews
was highly concentrated in particular pharmacies. Ranked
by volume of reviews performed, the top 25% of pharma-
cies accounted for almost three-quarters of all medication
reviews performed (72.4%), whereas the bottom 25%
accounted for fewer than 2% of medication reviews
performed.Prescription drug use and costs
In the MR-S cohort, the average number of prescriptions
per month ranged from 2.91 to 3.98. The average number of
prescriptions per patient was higher for the MR-PC cohort
(range, 3.47-4.83). We found statistically signiﬁcant level in-
creases in the number of prescriptions following a patient's
ﬁrst medication review for the MR-PC cohort (0.41 pre-
scriptions per patient [95% CI 0.14-0.68], P ¼ 0.006). We found
no statistically signiﬁcant changes in the trend for either
cohort following the index medication review.
This increase in prescription drug use corresponded to
an increase in total drug expenditure following a patient's
ﬁrst medication review. Total expenditure per patient per
month ranged from CAD $165 to $191 for the MR-PC cohort,
compared to CAD $142 to $162 for the MR-S cohort
(Figure 1). We found statistically signiﬁcant level increases
in the total expenditure per capita per month for both co-
horts (MR-S, $7.49 per capita per month [95% CI
$0.41e$14.6], P ¼ 0.048; MR-PC, $11.98 per capita per
month [95% CI $3.92e$20.04], P ¼ 0.007). We also found
statistically signiﬁcant decreases in the trend for both co-
horts following their index medication review (MR-
S, $1.27 per capita per month [95% CI $2.11 to $0.44]515
Table 1
Descriptive summary of the MR-S and MR-PC cohorts
Patient characteristics Type 1 (MR-S cohort) Type 2 (MR-PC cohort)
Total number of reviews 266,786 (89%) 31,533 (11%)
Total number of unique patients 147,770 16,006
Sex
Male 44% 40%
Female 56% 60%
Mean age (y) 59 63
Percent aged 65 y or older 46% 56%
Number of patients receiving a later review of a different type
MR-S d 4463 (30%)
MR-PC 5510 (3.5%) d
MR-F 16,853 (11%) 4364 (27%)
Percent that submitted claims for one of the following drugs
Proton pump inhibitors 35% 40%
Statins 46% 49%
Diabetes medications 23% 25%
Benzodiazepines 25% 27%
Anti-hypertensives 68% 73%
Proportion of pharmacies conducting reviews
Bottom 25% 1.2% 0.9%
Bottom 50% 7.6% 5.0%
Top 25% 73.1% 81.3%
Abbreviations used: MR-S, standard medication review; MR-PC, pharmacists consultation medication review; MR-F, follow-up medication review.
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SCIENCE AND PRACTICEP ¼ 0.006; MR-PC, $2.10 per capita per month [95%
CI $3.15 to $1.04], P ¼ 0.001). In contrast, our sensitivity
analysis found no statistically signiﬁcant changes in either
the level (MR-S, $3.24 per capita per month, P ¼ 0.367;
MR–PC, $6.94 per capita per month, P ¼ 0.113) or the trend
for either cohort (MR-S, $0.55 per capita per month, P ¼
0.220; MR-PC, $1.61 per capita per month, P ¼ 0.056).
Patient medication persistence
Our analyses found no change in the continuation of
several long-term chronic medications, including diabetes
medications and antihypertensives (Table 2). The one
exception was statin prescriptions, where we observed a
small level increase of 0.52% (95% CI 0.19%e0.86%, P ¼ 0.005)
in the MR-PC cohort. Similarly, we found no reductions in
continuations for PPIs and benzodiazepines. In contrast, we0 
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Figure 1. Observed total all-payer spending per capita in British Columbia between M
MR-S or an MR-PC (MR-S, $7.49 per capita per month [95% CI $0.41e$14.6], P ¼ 0.04
516actually observed a small increase in the trend of reﬁlling
benzodiazepines for both cohorts (MR–S, 0.14% per month
[95% CI 0.10%e0.19%], P ¼ 0.001; MR-PC, 0.34% per month
[95% CI 0.20%e0.48%], P ¼ 0.001; Figure 2). We also observed
an increase in the trend of reﬁlling PPI prescriptions for MR-
PC recipients (0.13% per month [95% CI 0.04%e0.21%], P ¼
0.007; Figure 3).
Potentially inappropriate prescriptions
The number of PIPs dispensed per patient increased after
the ﬁrst medication review for patients age 65 years and older
(Figure 4). This level change was present in both cohorts (MR-
S, 13.32 prescriptions per 1000 patients [95% CI 4.09e22.55],
P ¼ 0.009; MR-PC, 16.48 prescriptions per 1000 patients [95%
CI 1.93e31.02], P ¼ 0.035). We found no signiﬁcant changes in
the trend for either cohort.-3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 
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ay 1, 2012, and June 30, 2013, for patients whose ﬁrst medication review was an
8; MR-PC, $11.98 per capita per month [95% CI $3.92e$20.04], P ¼ 0.007).
Table 2
Level and trend changes in the proportion of prescriptions reﬁlled within the days' supply plus 30 days following a ﬁrst pharmacist medication review
Drug MR-S MR-PC
Level change (95% CI) P value Trend change (95% CI) P value Level change (95% CI) P value Trend change (95% CI) P value
Statins 0.39 (0.66 to 1.45) 0.472 0.02 (0.15 to 0.12) 0.815 0.52 (0.19e0.86) 0.005 0.02 (0.05 to 0.02) 0.440
Diabetes medications 0.42 (0.12 to 0.95) 0.142 0.021 (0.08 to 0.04) 0.521 0.44 (0.15 to 1.02) 0.154 0.01 (0.06 to 0.08) 0.847
Anti-hypertensives 0.15 (0.69 to 1.00) 0.723 0.01 (0.01 to 0.11) 0.920 0.04 (0.40 to 0.49) 0.849 0.03 (0.03 to 0.09) 0.371
Benzodiazepines 0.03 (0.42 to 0.35) 0.867 0.14 (0.10e0.19) <0.001 0.31 (0.75 to 1.38) 0.569 0.34 (0.20e0.48) <0.001
Proton pump inhibitors 0.25 (0.43 to 0.94) 0.476 0.01 (0.08 to 0.10) 0.821 0.23 (0.50 to 0.95) 0.546 0.13 (0.04e0.21) 0.007
MR-S, standard medication review; MR-PC, pharmacists consultation medication review.
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SCIENCE AND PRACTICEPharmacy use patterns
We found no evidence that medication reviews helped
patients consolidate pharmacy visits or increase loyalty to
particular pharmacies. For both cohorts, we observed an in-
crease in the number of pharmacy visits per month following
the ﬁrst medication review (MR-S, 0.06 visits per patient [95%
CI 0.02e0.10], P¼ 0.006; MR-PC, 0.12 visits per patient [95% CI,
0.07e0.16], P ¼ 0.001). We found no change in trend for the
MR-S cohort, but there was a trend decrease in the MR-PC
cohort (0.007 pharmacy visits per patient per month [95%
CI 0.014 to 0.001], P ¼ 0.030).
Counter to the hypothesis that medication reviews would
increase loyalty to a particular pharmacy, we found signiﬁcant
level increases in the number of unique pharmacies visited per
month following the ﬁrst medication review for both cohorts
(MR-S, 0.018 unique pharmacies per patient [95% CI
0.006e0.030], P ¼ 0.007; MR-PC, 0.013 unique pharmacies per
patient [95% CI 0.006e0.030], P ¼ 0.001). There were also
signiﬁcant decreases in the trend for both cohorts (MR-
S, 0.003 unique pharmacies per patient per month [95%
CI 0.005 to 0.002], P ¼ 0.001; MR-PC, 0.002 unique
pharmacies per patient per month [95% CI 0.005 to 0.002],
P¼ 0.001). The magnitude of this trend change in both cohorts
would have essentially cancelled out the level increase by
1-year post-medication review.0% 
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Figure 2. Observed benzodiazepine prescriptions reﬁlls within the days' supply plus
whose ﬁrst medication review was an MR-S or a nMR-PC (MR-S, 0.14% per month [9
P ¼ 0.001).Discussion
Over the past several years, most Canadian provinces have
expanded the scope of pharmacy practice to include the provi-
sion of medication reviews. In BC, this program has been pop-
ular,withmore thanCAD$16million of billings to the provincial
government in the 2013-2014 ﬁscal year.18 Despite this popu-
larity,we foundnomeaningful impactofpharmacistmedication
reviews inBConoveralldrugutilizationandcosts, persistence to
several popular medication classes, deprescribing of PIPs, or
pharmacyutilizationpatterns.Althoughwefoundthat the trend
inprescriptiondrug costsdecreased slightlypost-review inboth
cohorts, our sensitivity analysis excluding the month of the
medication review did not corroborate these ﬁndings. This
ﬁndingsuggests that theobserveddecrease is likelyanartifactof
patients receiving a review concurrently when they visited the
pharmacy to ﬁll a prescription. Taken together, our results sug-
gest that theprogramdidnot have aneffect onoptimizinguseof
medications and deprescribing inappropriate or unnecessary
medications.7
Our ﬁndings align with prior reviews suggesting limited
effectiveness for community pharmacy interventions.11 There
are several possible explanations for this. First, for pharmacist
recommendations to inﬂuence drug utilization, they have to
inﬂuence physician prescribing; however, evidence suggests
that such change is best achieved through direct interaction4 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 
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Figure 3. Observed proton pump inhibitor prescription reﬁlls within the days’ supply plus 30 days in British Columbia between May 1, 2012, and June 30, 2013, for
patients whose ﬁrst medication review was an MR-S or an MR-PC (MR-S, 0.01% per month [95% CI 0.08% to 0.10%], P ¼ 0.821; MR-PC, 0.13% per month [95% CI 0.04%e
0.21%], P ¼ 0.007).
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SCIENCE AND PRACTICEbetween the pharmacist and prescriber.14,32-35 BC medication
review guidelines do not require direct contact between the
pharmacists and prescribing physicians. Thus, the causal
mechanism through which community pharmacists might in-
ﬂuence medicine use is much more distal, perhaps explaining
the lack of effectiveness we observed.36,37 A second factor may
be an unwillingness of some physicians to review and act upon
documentation sent by pharmacists. A study of a similar pro-
gram in BC found that physicians believed they were not
adequately reimbursed to do so.16 Additionally, pharmacists
might not be correctly or appropriately identifying drug ther-
apy problems, might not be able to make effective changes in
response to identiﬁed problems, or might not be conducting0 
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Figure 4. Observed number of potentially inappropriate prescriptions dispensed per
patients whose ﬁrst medication review was an MR-S or an MR-PC (MR-S, 13.32 pre
scriptions per 1000 patients [95% CI 1.93e31.02], P ¼ 0.035).
518effective medication reviews. Finally, pharmacists have re-
ported not having enough time or resources to conduct medi-
cation reviews effectively.15,16 This may make it more difﬁcult
for pharmacists to appropriately target complex patients, for
example,whocouldbeneﬁtmost fromthis service. Pharmacists
in similar programs have also reported lacking access to rele-
vant and accurate clinical information about their patients,
leaving them unable to provide strong recommendations.37
Existing literature, and our study, demonstrate that
pharmacist-led interventions targeted at adults with poorly
controlled disease states, such as diabetes or hypertension, are
more effective than those programs targeted at adults or se-
niors in general.12,13,35 -3 -2 -1 1 2 3 4 5 6 7 8 9 10 11 12 
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SCIENCE AND PRACTICEThe design, purpose, and goals of medication reviews in
BC align closely with medication therapy management
(MTM) as deﬁned by the American Pharmacists Associa-
tion.38-41 Many of the shortcomings of the BC medication
review program, including limited potential to affect
physician prescribing and ineffective or poorly targeted
MTM meetings, could arise in MTM services provided by
pharmacists across North America. Thus, our ﬁndings are
relevant to pharmacy practice across Canada and in the
United States.
Limitations
The limitations to this study are worth noting. First, we
lacked information on actual recommendations that patients
received from the pharmacist; therefore, we could not spe-
ciﬁcally examine their implementation. Second, we have no
data on clinical diagnoses for patients, so we are not
fully able to assess the appropriateness of particular pre-
scriptions. However, Beer's Criteria are a validated tool and
would capture changes in the use of different PIPs over time,
as was done in this study.21 Third, we did not have any in-
formation on medicines received in hospital, as these are not
recorded in the PharmaNet database. Fourth, because Phar-
maNet does not provide information on over-the-counter
medications, we were not able to assess the impact of a
medication review conducted on the basis of a drug therapy
problem related to over-the-counter medication use. Finally,
we did not collect or examine data on clinical services use by
patients (e.g., emergency department visits, hospitaliza-
tions). However, it seems unlikely that health outcomes or
clinical services use would have changed in the absence of
any observable changes in prescription drug use or
persistence.
Conclusions
Our results indicate that medication reviews performed by
community pharmacists in BC had little impact, at consider-
able cost to the provincial government, on the prescription
drug use outcomes we examined. While all but 2 provinces in
Canada offer these types of medication reviews, this study
represents the ﬁrst quantitative evaluation of these services.
Future iterations of medication review programs might
consider a more targeted approach. For example, programs
could focus on patients who meet multiple criteria of clinical
need, are high-cost drug users, or have speciﬁc and remediable
medication issues. The program could also require contact that
is more direct or an existing relationship between pharmacists
and patients' prescribing physicians. Overall, our results sug-
gest that medication review programs should be modiﬁed and
evaluated to ensure value for money in this line of pharmacy
services.
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SCIENCE AND PRACTICEAppendix 1
Generalized least-squares (GLS) regression extends ordinary
least-squares estimation of the normal linear model by
providing for possibly unequal error variances and for correla-
tions between different errors. A common application of GLS
estimation is to time-series regression, in which it is generally
implausible to assume that errors are independent. One can
detect autocorrelation in time series data, and available statis-
tical software can control for it. For details of application to
time series data using the GLS function in the R nlme package,
please see Fox and Weisberg (2011).a
Autocorrelation canbe detected visually by inspecting a plot
of the residuals over time and by conducting statistical tests
(i.e., Durbin-Watson statistics). Randomly scattered residualsa Fox J, Weisberg S. An R Companion to Applied Regression, second edition.
Thousand Oaks, CA: Sage; 2011.with no discernable pattern indicate no autocorrelation. The
acf function in the R stats package computes andplots the auto-
correlation and partial-autocorrelation functions of a time
series. The general pattern of the autocorrelation and partial-
autocorrelation functions can be used to specify a model for
error autocorrelation.
In our study, a time series is divided into 2 segments sepa-
rated by an intervention. The ﬁrst segment includes a series of
18 preintervention observations that establish a baseline trend.
The intervention occurs at a known time and then is followed
with a series of 12 postintervention observations from which
we can analyze the impact of the intervention. The goal is to
demonstrate a clear causal relationship between an interven-
tion and an outcome after ruling out other forces that might
have had the same outcome in the absence of the intervention.520.e1
